Ashwini M. Shadakshari

Ashwini M. Shadakshari

Rheumatology

28100 Grand River Avenue
Suite 314
Farmington Hills, MI 48336

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2 publications

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Journal: Lancet (London, England)

Published: October 03, 2017

Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 06, 2013

Showing 1-2 of 2

Last Updated: 09/26/2026